NASDAQ:LIMN Liminatus Pharma (LIMN) Stock Price, News & Analysis $3.34 -0.07 (-1.91%) As of 02:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Liminatus Pharma Stock (NASDAQ:LIMN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Liminatus Pharma alerts:Sign Up Key Stats Today's Range$3.27▼$3.5550-Day Range$3.33▼$7.5052-Week Range$3.27▼$141.50Volume17,101 shsAverage Volume339,708 shsMarket Capitalization$4.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA. Read More Liminatus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreLIMN MarketRank™: 0.949724337095 of 5 starsLiminatus Pharma scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLiminatus Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLiminatus Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Liminatus Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Liminatus Pharma is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Liminatus Pharma is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.12% of the float of Liminatus Pharma has been sold short.Short Interest Ratio / Days to CoverLiminatus Pharma has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Liminatus Pharma has recently decreased by 24.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLiminatus Pharma does not currently pay a dividend.Dividend GrowthLiminatus Pharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentLiminatus Pharma has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Liminatus Pharma this week, compared to 1 article on an average week.Search Interest2 people have searched for LIMN on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Liminatus Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.40% of the stock of Liminatus Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsLiminatus Pharma has minimal institutional ownership at this time.Read more about Liminatus Pharma's insider trading history. Receive LIMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liminatus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIMN Stock News HeadlinesLiminatus Pharma Inc. (NASDAQ:LIMN) Shares Shorted: Short Interest Down 38.4% in SeptemberOctober 3, 2026 | americanbankingnews.comLiminatus Pharma Regains Nasdaq Compliance Following 1-For-50 Reverse SplitSeptember 30, 2026 | rttnews.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 14 at 1:00 AM | Paradigm Press (Ad)Liminatus Pharma regains NASDAQ complianceSeptember 29, 2026 | msn.comLiminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price RuleSeptember 29, 2026 | globenewswire.comLiminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapyAugust 24, 2026 | globenewswire.comLiminatus Pharma, Inc. Announces Reverse Stock Split of its Common StockAugust 18, 2026 | globenewswire.comLiminatus Pharma Inc (LIMN)August 14, 2026 | investing.comSee More Headlines LIMN Stock Analysis - Frequently Asked Questions How have LIMN shares performed this year? Liminatus Pharma's stock was trading at $30.50 at the beginning of the year. Since then, LIMN stock has decreased by 89.0% and is now trading at $3.3630. How were Liminatus Pharma's earnings last quarter? Liminatus Pharma Inc. (NASDAQ:LIMN) posted its earnings results on Saturday, October, 4th. The company reported ($2.50) earnings per share (EPS) for the quarter. When did Liminatus Pharma's stock split? Liminatus Pharma's stock reverse split on Friday, August 21st 2026.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 20th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Liminatus Pharma? Shares of LIMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings10/04/2025Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LIMN Previous SymbolNASDAQ:LIMN CIK1971387 Webliminatuspharma.com Phone(213) 273-5453FaxN/AEmployees1Year Founded1996Profitability EPS (Trailing Twelve Months)($23.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.21 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-256.58% Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio1.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($18.13) per share Price / Book-0.18Miscellaneous Outstanding Shares1,340,000Free Float1,082,000Market Cap$4.48 million OptionableN/A Beta4.97 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:LIMN) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredIf you think you’re late to AI, see this nowTech leaders like Microsoft's Satya Nadella and Goldman Sachs' David Solomon say AI's infrastructure buildout ...Weiss Ratings | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
